Harris Associates L P 13F: Adds $320M to ICON Public (ICLR) Stake

Harris Associates L P has significantly increased its stake in ICON Public Limited Company (NasdaqGS: ICLR). As of the latest 13F filing with the SEC, the fund added 1,841,151 shares, boosting its holdings by 73.3% to a total of 4,351,317 shares, valued at approximately $700.39 million.

What Changed in Harris Associates's ICON Public Limited Company Position

Harris Associates increased its position in ICON Public Limited Company by 73.3%, according to the latest filing. The fund now holds 4,351,317 shares, up from 2,510,166 shares previously, adding 1,841,151 shares. The reported value of this stake is about $700.39 million.

Other Institutional Activity in ICON Public Limited Company

In addition to Harris Associates, several other institutional investors adjusted their positions in ICON Public Limited Company. Artisan Partners Limited Partnership grew its holdings by 1,404,968 shares, ending with 8,278,945 shares worth approximately $916.15 million. Wellington Management Group LLP increased its position by 1,562,287 shares to a total of 5,913,037 shares, valued at around $654.34 million. FMR LLC added 1,076,111 shares, bringing its total to 4,174,006 shares valued at roughly $461.90 million. Invesco Ltd. also increased its stake by 121,973 shares, now holding 3,878,869 shares worth about $429.24 million.

ICON Public Limited Company Stock Up 5.8%

Shares of ICON Public Limited Company traded near $160.96 on Friday. The company has a market capitalization of $12.33 billion and a P/E ratio of 70.91, with a forward P/E of 13.62. The stock's 52-week range is between $66.57 and $211.00. Its 50-day moving average is $127.80, while the 200-day moving average stands at $149.18. The company has a current ratio of 1.14 and a quick ratio of 1.09, with a debt-to-equity ratio of 37.72.

Recent Earnings

For its recent quarter, ICON Public Limited Company reported revenue of $8.27 billion, reflecting a growth of 1.6%. The company posted an EPS of $2.27, with a net margin of 2.1% and a return on equity of 1.8%. ICON is expected to report its next earnings on June 23, 2026.

Insider Buying and Selling at ICON Public Limited Company

Recent insider activity at ICON Public Limited Company included several transactions on May 14, 2026. Dr. John Climax bought and sold 5,005 shares, while Ronan Martin Murphy also executed similar transactions. Eugene Pacelli McCague bought and sold 3,255 shares. These transactions were not under Rule 10b5-1 plans.

Analysts Set New Price Targets

On June 25, 2026, several analysts updated their ratings and price targets for ICON Public Limited Company. RBC Capital upgraded the stock to a 'buy' with a $185 price target. Citigroup maintained a 'hold' rating and a $165 target, while BMO Capital and TD Cowen both maintained 'buy' ratings with targets of $187 and $197, respectively. The consensus among 16 analysts is a 'buy' rating, with an average target price of $175.31.

About ICON Public Limited Company

ICON Public Limited Company is a clinical research organization based in Dublin, Ireland. It provides outsourced development and commercialization services, specializing in clinical development from compound selection to Phase I-IV studies. With approximately 40,100 employees, ICON serves the pharmaceutical, biotechnology, and medical device industries globally. The company is led by CEO Mr. Barry Balfe and has a strategic alliance with Advarra, Inc. for clinical trial site network development.

Bottom Line

Harris Associates' substantial increase in its stake in ICON Public Limited Company highlights the firm's confidence in the company's prospects. Investors closely monitor these filings as they offer insights into institutional sentiment. Remember, 13F filings reflect past positions and may not indicate current holdings.